scanX
Aurobindo Pharma
add_icon

Aurobindo Pharma

1,330.90
-2.80
(-0.21%)
Market Cap
77,298.89 Cr
PE Ratio
22.27
Volume
9,77,007.00
Day High - Low
1,357.90 - 1,318.50
52W High-Low
1,359.90 - 1,010.00
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
77,298.89 Cr
EPS
59.81
PE Ratio
22.27
PB Ratio
2.21
Book Value
603.32
EBITDA
7,204.60
Dividend Yield
0.00 %
Industry
Healthcare
Sector
Pharmaceuticals
Return on Equity
10.67
Debt to Equity
0.24
Analyst Rating and Forecast
- By Refinitiv from26 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+80.77 %
+80.77 %
Hold
Hold+3.85 %
+3.85 %
Sell
Sell+15.38 %
+15.38 %
Forecast For
Actual

Company News

View All News
Caret
positive
Aurobindo Pharma Approves ₹800 Cr Share BuybackToday
Aurobindo Pharma board approved buyback of 54.24 lakh equity shares at ₹1,475 per share for ₹800 crores, representing 0.93% of paid-up capital with record date April 17, 2026.
neutral
Aurobindo Pharma Transfers Domestic Business UnitToday
Aurobindo Pharma's board approved transfer of domestic branded generic pharmaceutical formulations business to wholly owned subsidiary Auropharm Limited for INR 143.21 crores consideration.
neutral
Aurobindo Pharma Extends Solar Acquisition Timeline6 days ago
Aurobindo Pharma extends timeline to acquire 26% stake in Swarnaakshu Solar to June 30, 2026, pending state government approval for captive solar power plant project.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,682.10
#1 4,03,592.14
37.12
#1 54,729.00
9.71
#1 10,980
16.07
37.98
Divis Laboratories
5,807.50
1,54,170.88
62.72
9,712.00
18.67
2,191
-1.02
33.24
Torrent Pharmaceuticals
3,997.50
1,35,293.56
59.42
11,539.40
6.99
1,911
26.24
32.75
Lupin
2,247.00
1,02,697.61
22.29
22,909.50
13.74
3,306
#1 37.44
47.35
Dr Reddys Laboratories
1,206.50
1,00,699.68
18.40
33,741.20
16.73
5,725
-15.28
39.36
Cipla
1,185.60
95,770.48
21.27
28,409.50
7.12
5,291
-57.18
26.86
Zydus Life Science
860.55
86,591.47
#1 17.30
23,511.00
18.55
4,615
-0.32
41.42
Mankind Pharma
1,999.70
82,548.63
45.73
12,744.20
#1 20.90
2,007
7.65
41.40
Aurobindo Pharma
1,330.10
#9 77,252.42
#4 22.27
#3 32,345.60
#7 9.43
#5 3,484
#5 7.59
64.38
Alkem Laboratories
5,184.50
61,988.47
25.95
13,458.30
3.70
2,216
1.90
42.54

Automatic Screeners on ScanX

Community
1% near 52 Week High
Community
5% near 52 Week High
Growth Rate
Revenue Growth
9.43 %
Net Income Growth
9.93 %
Cash Flow Change
61.21 %
ROE
0.47 %
ROCE
10.77 %
EBITDA Margin (Avg.)
2.86 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Revenue
3,151
3,272
3,324
3,450
3,710
3,728
3,742
3,871
3,625
3,645
4,366
4,302
4,033
4,226
4,694
5,242
5,234
5,377
5,539
5,830
6,108
5,951
6,432
9,300
6,071
5,802
5,987
6,089
5,844
6,218
5,731
6,481
6,514
6,907
7,339
7,434
7,628
7,679
7,783
8,052
8,516
7,899
8,359
8,793
Expenses
2,506
2,574
2,586
2,688
2,885
2,878
2,847
3,011
2,920
2,845
3,319
3,311
3,261
3,539
3,792
4,208
4,271
4,311
4,473
4,701
4,862
4,679
5,071
5,011
4,735
4,502
4,766
4,993
5,002
5,303
4,950
5,453
5,477
5,772
5,846
5,753
6,042
5,949
6,230
6,401
6,622
6,265
6,608
6,938
EBITDA
645
698
738
762
825
851
895
860
704
800
1,047
992
772
687
902
1,033
963
1,066
1,066
1,130
1,247
1,271
1,361
4,290
1,335
1,300
1,220
1,096
842
914
781
1,027
1,037
1,135
1,493
1,681
1,585
1,730
1,553
1,652
1,894
1,634
1,752
1,855
Operating Profit %
20 %
21 %
22 %
22 %
21 %
22 %
23 %
22 %
18 %
21 %
24 %
22 %
18 %
15 %
19 %
19 %
18 %
20 %
19 %
19 %
20 %
20 %
20 %
21 %
21 %
21 %
19 %
17 %
14 %
14 %
13 %
15 %
14 %
15 %
18 %
21 %
19 %
20 %
19 %
19 %
21 %
20 %
20 %
19 %
Depreciation
85
89
93
99
111
106
110
111
100
131
132
138
157
155
164
163
187
241
243
250
232
256
257
277
266
280
294
299
254
280
298
321
346
327
418
423
354
404
382
419
444
406
429
465
Interest
21
31
68
9
25
21
18
14
14
17
17
19
25
30
35
48
50
50
41
37
32
21
16
20
18
13
10
16
9
15
25
45
56
57
68
76
89
111
113
119
115
98
95
93
Profit Before Tax
557
634
631
717
761
786
830
796
649
709
979
902
651
571
787
917
816
863
864
938
1,078
1,084
1,193
4,005
1,061
1,018
968
794
594
679
523
680
730
812
1,076
1,262
1,230
1,324
1,208
1,200
1,335
1,207
1,276
1,339
Tax
153
162
178
173
206
201
224
218
117
191
198
307
122
116
175
205
231
228
224
233
229
301
386
1,058
260
248
271
190
18
159
113
189
224
242
324
323
323
406
391
354
432
383
428
429
Net Profit
403
472
453
545
555
585
606
579
532
518
781
595
529
456
611
712
585
636
640
705
849
783
807
2,948
801
770
697
604
576
520
410
491
506
570
752
940
907
918
817
846
903
824
848
910
EPS in ₹
13.84
16.18
7.77
9.32
9.49
9.99
10.41
9.88
9.10
8.85
13.33
10.16
9.02
7.78
10.44
12.15
9.99
10.85
10.92
12.04
14.50
13.32
13.78
50.31
13.67
13.14
11.89
10.32
9.84
8.88
6.99
8.38
8.64
9.74
12.83
16.04
15.51
15.69
14.00
14.56
15.56
14.20
14.61
15.67
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
12,915
15,920
16,249
21,101
26,454
28,928
33,854
33,922
39,890
45,072
49,785
Fixed Assets
3,706
4,180
4,834
6,521
8,475
9,397
9,374
10,532
11,024
14,493
14,794
Current Assets
8,299
10,294
9,206
12,178
15,332
16,413
19,824
18,123
21,460
23,772
27,163
Capital Work in Progress
420
848
1,458
1,583
1,669
1,986
3,062
3,747
5,390
3,869
4,900
Investments
20
123
246
312
360
555
591
997
543
372
252
Other Assets
8,770
10,769
9,712
12,686
15,951
16,991
20,828
18,645
22,934
26,338
29,839
Total Equity & Liabilities
12,915
15,920
16,249
21,101
26,454
28,928
33,854
33,922
39,890
45,072
49,785
Current Liabilities
6,136
7,840
6,606
8,666
12,021
11,385
10,665
8,156
11,494
12,199
14,682
Non Current Liabilities
1,596
790
270
753
541
718
1,260
1,192
1,544
3,022
2,456
Total Equity
5,182
7,290
9,374
11,682
13,892
16,825
21,929
24,574
26,852
29,851
32,647
Reserve & Surplus
5,127
7,229
9,313
11,622
13,832
16,766
21,871
24,517
26,781
29,784
32,595
Share Capital
29
59
59
59
59
59
59
59
59
59
58
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
313
340
-424
892
666
871
2,561
-1,164
230
-1,007
2,178
Investing Activities
-1,017
-1,446
-1,787
-1,927
-2,904
-1,563
597
-3,211
-3,971
-4,242
-1,866
Operating Activities
1,237
1,420
3,279
1,955
1,651
4,381
3,329
5,017
2,387
2,435
3,925
Financing Activities
93
365
-1,915
864
1,919
-1,947
-1,365
-2,969
1,814
800
120
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Promoter
51.94 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.80 %
51.82 %
51.82 %
51.82 %
51.82 %
51.82 %
51.82 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.00 %
0.00 %
0.00 %
0.00 %
18.02 %
16.73 %
16.59 %
16.29 %
15.33 %
14.37 %
14.21 %
13.94 %
DIIs
10.99 %
12.72 %
13.82 %
15.11 %
15.83 %
15.58 %
16.23 %
14.89 %
15.08 %
15.73 %
17.94 %
20.23 %
23.28 %
24.77 %
25.13 %
25.20 %
26.23 %
26.93 %
27.60 %
27.68 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
8.71 %
8.54 %
9.60 %
8.99 %
8.37 %
8.80 %
8.65 %
9.42 %
8.54 %
7.01 %
6.15 %
5.64 %
5.52 %
5.47 %
5.33 %
5.52 %
5.47 %
5.67 %
5.25 %
5.36 %
Others
28.36 %
26.91 %
24.74 %
24.07 %
23.97 %
23.79 %
23.29 %
23.85 %
24.54 %
25.42 %
24.07 %
22.29 %
1.36 %
1.23 %
1.13 %
1.17 %
1.15 %
1.20 %
1.13 %
1.19 %
No of Share Holders
2,32,634
2,43,315
3,29,940
3,41,568
3,38,639
3,59,684
3,58,459
3,69,828
3,43,617
2,93,214
2,59,638
2,41,944
2,44,575
2,38,622
2,48,488
2,57,962
2,69,323
2,72,208
2,47,662
2,36,859

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 3.2 2.5 2.5 3 4 9 7.5 4.5 0.00 0.00
Dividend Yield (%) 0.57 0.32 0.61 0.34 0.6 1.77 0.69 0.39 0.00 0.00

Announcements

Intimation Of Record Date For Buyback4 hrs ago
Transfer Of Companys Domestic Branded Pharmaceutical Formulation Business To Auropharm Limited A Wholly Owned Subsidiary Of The Company.4 hrs ago
Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors - Buyback Of Shares4 hrs ago
Board Meeting Intimation for To Consider Inter Alia A Proposal For Buyback Of The Fully Paid-Up Equity Shares Of The Company5 days ago
Update On Solar Power Purchase Agreement And Acquisition Upto 26% Stake In Swarnaakshu Solar Power Private Limited.6 days ago
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report7 days ago
Entry Into Marketing And Distribution Agreement For Biosimilars In EU Territories By Curateq Biologics Private LimitedMar 25, 2026
Closure of Trading WindowMar 23, 2026
Classification Of Unit-V Of Apitoria Pharma Limited A Wholly Owned Subsidiary Of The Company As VAI By The US FDAMar 20, 2026
Classification Of Unit-II Of Eugia Pharma Specialities Limited A Wholly Owned Subsidiary Of The Company As OAI By The US FDAMar 17, 2026
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 13, 2026
Classification Of Unit-IV Of APL Healthcare Limited A Wholly Owned Subsidiary Of The Company As VAI By The US FDA - Reg.Mar 12, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 11, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 11, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 09, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 04, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 02, 2026
Clarification On Media Report Aurobindo PharmaS P Sarath Chandra Reddy Acquitted In Delhi Liquor Scam Case. Mar 02, 2026
Clarification sought from Aurobindo Pharma LtdFeb 27, 2026
Completion Of US FDA Inspection At Unit I Of Eugia Pharma Specialities LtdFeb 27, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 26, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 25, 2026
Announcement under Regulation 30 (LODR)-AcquisitionFeb 24, 2026
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 24, 2026
Intimation Of Orders Passed By The Goods & Services Tax DepartmentFeb 19, 2026
Clarification On News Item Appearing In Https://Www.Ndtvprofit.Com/"Feb 18, 2026
Clarification sought from Aurobindo Pharma LtdFeb 18, 2026
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 16, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 13, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 13, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 11, 2026
Completion Of US FDA Inspection At Unit-VII Of Aurobindo Pharma Limited JedcherlaFeb 10, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 10, 2026
Announcement under Regulation 30 (LODR)-RestructuringFeb 09, 2026
Announcement under Regulation 30 (LODR)-AcquisitionFeb 09, 2026
Announcement under Regulation 30 (LODR)-Change in DirectorateFeb 09, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 09, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 09, 2026
Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025Feb 09, 2026
Board Meeting Outcome for Outcome Of Board MeetingFeb 09, 2026
Completion Of US FDA Inspection At Unit III Of Eugia Pharma Specialities Ltd. A Wholly Owned Subsidiary Of The CompanyFeb 06, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 05, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 05, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 02, 2026
Clarification On Significant Volume Movement In CompanyS SharesFeb 02, 2026
Clarification sought from Aurobindo Pharma LtdFeb 01, 2026
Clarification On Significant Volume Movement In CompanyS SharesJan 31, 2026
Board Meeting Intimation for Intimation Of Board Meeting DateJan 30, 2026
Announcement under Regulation 30 (LODR)-AcquisitionJan 23, 2026
Curateq Biologics Receives NOC From Health Canada For Its Biosimilar DyrupegJan 09, 2026

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Bandhan Multi-Factor Fund Direct - Growth
3.76%
133384
2.47%
3.76%
JioBlackRock Flexi Cap Fund Direct-Growth
0.17%
37992
0.17%
0.17%
Sundaram Multi-Factor Fund Direct-Growth
1.13%
32248
0.39%
0.41%
Old Bridge Arbitrage Fund Direct-Growth
1.24%
11000
1.07%
1.06%
UTI Nifty500 Shariah Index Fund Direct-Growth
0.61%
3367
0.61%
0.61%
The Wealth Company Arbitrage Fund Direct-Growth
1.18%
-2200
0.06%
-0.14%
Franklin India Multi-Factor Fund Direct - Growth
0.71%
1739
0.00%
0.71%
JioBlackRock Sector Rotation Fund Direct - Growth
0.17%
1523
0.17%
0.17%
JioBlackRock Nifty Midcap 150 Index Fund Direct-Growth
0.90%
1280
0.00%
0.04%
Tata Nifty Midcap 150 Index Fund Direct-Growth
0.90%
899
-0.01%
0.04%
DSP Nifty Healthcare Index Fund Direct-Growth
3.40%
504
-0.20%
0.03%
Kotak Nifty Midcap 150 Index Fund Direct - Growth
0.90%
180
-0.01%
0.04%
Nippon India Nifty India Manufacturing Index Fund Direct - Growth
0.88%
113
-0.04%
0.00%
Navi Nifty MidSmallcap 400 Index Fund Direct - Growth
0.60%
-67
0.01%
0.04%
DSP Nifty Midcap 150 Index Fund Direct - Growth
0.90%
60
-0.01%
0.04%
Groww Nifty Midcap 150 Index Fund Direct - Growth
0.90%
32
-0.01%
0.04%
DSP Nifty 500 Index Fund Direct-Growth
0.17%
-11
-0.01%
0.17%
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.17%
8
0.00%
0.01%
LIC MF Equity Savings Fund Direct-Growth
0.00%
0
0.00%
-0.95%
ICICI Prudential Business Cycle Fund Direct - Growth
0.00%
0
0.00%
0.00%
Bajaj Finserv Multi Asset Allocation Fund Direct-Growth
0.63%
0
0.00%
-0.22%
Bajaj Finserv Multi Cap Fund Direct-Growth
1.69%
0
0.00%
-1.09%
Bandhan Arbitrage Fund Direct-Growth
0.52%
0
0.00%
-0.09%
Bandhan Balanced Advantage Fund Direct-Growth
0.61%
0
0.00%
-0.30%
Bandhan BSE Healthcare Index Fund Direct-Growth
2.50%
0
0.00%
-0.15%

Technical Indicators

RSI(14)
Neutral
64.38
ATR(14)
Volatile
41.17
STOCH(9,6)
Neutral
74.13
STOCH RSI(14)
Neutral
62.67
MACD(12,26)
Bullish
3.08
ADX(14)
Weak Trend
13.21
UO(9)
Bearish
58.67
ROC(12)
Uptrend And Accelerating
2.87
WillR(14)
Neutral
-21.85
Bearish
2
Neutral
5
Bullish
2

About Aurobindo Pharma

Aurobindo Pharma Limited (APL) is an Indian pharmaceutical company founded in 1986. It manufactures and markets active pharmaceutical ingredients, generic formulations, and branded pharmaceuticals globally. APL specializes in various therapeutic areas including antibiotics, antiretrovirals, cardiovascular, central nervous system, and gastroenterological products. The company operates 24 manufacturing plants worldwide and has...more
Website
https://www.aurobindo.com
Chairperson NameM R Kumar
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Technical Screeners
Intraday Screeners
Price & Volume Screeners
Candlestick Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 - 2026 Raise Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104